Immunic
Immunic, Inc., a New York‑based biotech developing oral immunology therapies for chronic inflammatory and autoimmune diseases. Lead assets IMU‑838 (Phase 3 for multiple sclerosis and ulcerative colitis) and IMU‑856 (Phase 2 barrier repair) aim to capture a growing market.
Headquarters: Germany (DEU)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 90
- HQ: New York
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.